Taysha Gene Therapies price to book ratio TSHA

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 3.3×
6-year median: 4.2×
Against its 6-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
6-year range: 1.4× to 58.2×
Peer median: 5.4×

Taysha Gene Therapies' price to book ratio is 3.3× as of Oct 23, 2026.

That is below its 6-year median of 4.2×, lower than on 77% of days in the last 6 years.

Over that time it ranged from 1.4× in May 2022 to 58.2× in Apr 2023.

The median for 7 biotech stocks of a similar size is 5.4×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.3×	3.0×	9.2×
2025	7.3×	3.1×	11.1×
2024	4.0×	2.8×	13.8×
2023	47.7×	3.8×	58.2×
2022	12.7×	1.4×	13.2×
2021	3.2×	2.9×	4.4×
2020	3.7×	2.8×	3.8×

Against its peers

Companies in Biotechnology nearest Taysha Gene Therapies' size, closest first, today.

Company	Price to book ratio
TSHATaysha Gene Therapies	3.3×
MGTXMeiraGTx	4.1×
VCELVericel	5.9×
ADMAAdma Biologics	5.9×
PLXProtalix BioTherapeutics	2.9×
KRYSKrystal Biotech	6.8×
RGENRepligen	4.7×
TECHBIO-TECHNE	5.4×
Peer median	5.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Taysha Gene Therapies

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.